Physicians' Academy for Cardiovascular Education

Agenda Topics ▼On-demand Online-CME Podcasts News ▼Meeting Reports Slides ▼About

ACC 2020 ▼AHA 2020 ▼Covid-19 ▼Diabetes & CVD ▼ESC 2020 ▼HF Practical Tutorials ▼Kidney disease & CVD ▼LDL-c goal attainment in high risk patients ▼

HoFH

Feb. 8, 2015

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist needs to know about GLP-1RA

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD

Similar risk reductions in MACE with achieved LDL-c <25 mg/dL and 25-50 mg/dL with PCSK9i

Literature - Feb. 18, 2021 - Schwartz GG, et al. - Circulation. 2021

Similar risk of NACE when comparing two P2Y12 inhibitors in patients with ACS after PCI

Literature - Dec. 15, 2020 - You SC, et al. - JAMA. 2020

Atherosclerosis

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

People aged 70-100 years with elevated LDL-c are at high risk of MI and ASCVD

Literature - Jan. 21, 2021 - Mortensen MB & Nordestgaard BG., - Lancet. 2020

Silent CAD present in 4 out of 10 Swedish individuals

News - Nov. 14, 2020

Atrial fibrillation

Modified CHADS2 shows best predictive performance for stroke across spectrum of kidney function

Literature - Apr. 13, 2021 - De Jong Y et al. - Eur Heart J. 2021

Causal relationship between blood pressure and AF risk

Literature - Mar. 2, 2021 - Georgiopoulos G, et al. - Eur J Prev Cardiol. 2021

Enhanced safety advantage with DOAC in women with AF

Literature - Mar. 1, 2021 - Zelniker TA et al. - Circulation. 2021

BET Inhibition

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Primary endpoint not met for BET inhibitor in phase 3 trial

News - Sep. 30, 2019

BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?

10' education - Sep. 30, 2019 - Prof. Wouter Jukema

Covid-19

Clinical resemblance of heparin-induced thrombocytopenia in some cases after COVID-19 vaccination

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Risk of ischemic stroke in patients hospitalized with COVID-19 in the USA

News - Mar. 19, 2021

Lower rate of cholesterol testing during COVID-19 pandemic

Literature - Mar. 3, 2021 - Gumuser ED, et al. - Am J Prev Cardiol 2021

Covid-19, ACE2, RAASi

COVID-19, ACE2 and RAAS inhibition

Online-CME - This course consists of 3 parts.

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD

CV Inflammation

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD

Anti-inflammatory treatment within 3 days after MI improves CV outcomes

Literature - Jan. 25, 2021 - Bouabdallaoui N, et al. - Eur Heart J. 2020

Endothelial injury and dysfunction in COVID-19

Literature - Jan. 19, 2021 - Evans PC et al., - Cardiovasc Res. 2020

CVRM

The role for primary care in reducing CV risk in diabetes

10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD

The mechanism of action of bempedoic acid

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Diabetes

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

NT-proBNP outperforms ESC/EASD risk model for 10-year fatal CVD risk prediction in T2DM cohort

Literature - Mar. 5, 2021 - Prausmüller S, et al. - Cardiovasc Diabetol. 2021

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

Diabetes & CVD

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

NT-proBNP outperforms ESC/EASD risk model for 10-year fatal CVD risk prediction in T2DM cohort

Literature - Mar. 5, 2021 - Prausmüller S, et al. - Cardiovasc Diabetol. 2021

Epigenetics in CVD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

BET inhibitor therapy did not meet primary endpoint of reducing MACE in post-ACS patients with T2DM

News - Nov. 17, 2019

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Familial Hypercholesterolemia

Registry data of PCKS9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

Registry data of PCSK9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

FDA approves PCSK9 inhibitor for patients with HoFH

News - Apr. 6, 2021

German videos

Möglichkeiten in der Lipidtherapie die unabhängig vom LDL-c das residuale Risiko reduzieren

Residuales Risiko: Die Rolle der Hypertriglyceridämie

GLP-1 RA & CVD

Two phase 3 trials with dual GIP/GLP-1RA in T2DM meet primary and key secondary endpoints

News - Feb. 23, 2021

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

Sustained body weight loss with GLP-1RA in individuals with overweight or obesity

Literature - Feb. 17, 2021 - Wilding JPH, et al. - N Engl J Med. 2021

Heart Failure

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Ambient air pollution associated with increased risk of incident HF

Literature - Mar. 15, 2021 - Wang M et al. - Eur Heart J. 2021

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

HFpEF: The essentials to know

HFpEF: Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME

Slides: HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

Slides (presentation) - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

HFpEF: How to diagnose

10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME

Hypertension

Nearly linear relationship between sodium intake and BP in individuals with and without hypertension

Literature - Mar. 16, 2021 - Filippini T, et al. - Circulation. 2021

CVD risk associated with lower SBP range in women than in men

Literature - Mar. 5, 2021 - Ji H et al. - Circulation. 2021.

An overview of the global burden of CVD and risk factors from 1990 to 2019

Literature - Jan. 14, 2021 - Roth GA, et al. - J Am Coll Cardiol. 2020

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME

Kidney disease & CVD

Modified CHADS2 shows best predictive performance for stroke across spectrum of kidney function

Literature - Apr. 13, 2021 - De Jong Y et al. - Eur Heart J. 2021

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

LDL-c Key Lessons

Key lessons on LDL-c and CV risk

LDL-c Key lessons

Screening for familial hypercholesterolemia after ACS pays off

LDL-c Key Lessons

LDL-c lowering treatment impacts disease progression before clinical manifestation

LDL-c Key Lessons

Lipids

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

ApoB and non-HDL-c are better markers of residual risk than LDL-c in statin-treated patients

Literature - Apr. 7, 2021 - Johannesen CDL et al. - J Am Coll Cardiol. 2021

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

Lp(a)

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

Elevated Lp(a) associated with CAD in individuals without a family history of CVD

Literature - Mar. 8, 2021 - Finneran P et al. - J Am Heart Assoc. 2021

E-learning Lp(a), a new lipid frontier in CV risk management

Online-CME - This course consists of 3 parts.

PCSK9

Registry data of PCKS9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

Registry data of PCSK9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD

Pulmonary Arterial Hypertension

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

Literature - June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

SGLT2i

Sustained benefit of SGLT2i in HFrEF by 28 days

Literature - Mar. 31, 2021 - Berg DD, et al. - JAMA Cardiology 2021

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

siRNA therapy and LDL-C

The gap between guideline LDL-c goals and current practice: how are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

PCSK9 siRNA recommended by CHMP for EU approval

News - Oct. 28, 2020

Stroke

Modified CHADS2 shows best predictive performance for stroke across spectrum of kidney function

Literature - Apr. 13, 2021 - De Jong Y et al. - Eur Heart J. 2021

Lower dose DOAC reduces net clinical outcome in patients with AF

Literature - Mar. 29, 2021 - Steffel J et al. - J Am Coll Cardiol. 2021

Elevated Lp(a) associated with large artery atherosclerosis stroke and risk of recurrent stroke

Literature - Mar. 23, 2021 - Arnold M et al. - Eur Heart J. 2021

© 2006 - 2021 pace-cme.org - About